21 An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)
Necchi, A., Magazzu’, D., Anichini, A., Raggi, D., Giannatempo, P., Nicolai, N., Colecchia, M., Paolini, B., Coradeschi, E., Tassi, E., Grazia, G., Mortarini, R., Calareso, G., Togliardi, E., Crippa,Volume:
15
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/s1569-9056(16)60023-4
Date:
March, 2016
File:
PDF, 201 KB
english, 2016